Farmácia/Notícias da Indústria

Estudo de coorte | Incidência da síndrome de Guillain-Barré após vacinação contra Covid-19.

28 Abr, 2022 | 12:07h

Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink – JAMA Network Open

 

Comentário no Twitter

This cohort study of #COVID19 vaccine safety surveillance in the US Vaccine Safety Datalink found a small elevated risk of Guillain-Barré syndrome after Janssen/J&J vaccine but not after mRNA COVID-19 vaccines. @KPDOR https://t.co/TTya5BDqeV

— JAMA Network Open (@JAMANetworkOpen) April 26, 2022

 

---

Revisão | Uso de antibióticos para infecções de corrente sanguínea na UTI.

28 Abr, 2022 | 11:44h

Use of Antimicrobials for Bloodstream Infections in the Intensive Care Unit, a Clinically Oriented Review – Antibiotics

---

Sim, recaídas após Paxlovid acontecem – e agora?

27 Abr, 2022 | 16:33h

Yes, Relapses After Paxlovid Happen — Now What? – HIV and ID Observations

 

Comentário no Twitter

Some additional thoughts about relapsing Covid19 after treatment with Paxlovid.

Bottom line — *lots* of unknowns, starting w/ how often it happens.

Looking forward to @pfizer sharing further data on the relapsing cases from their EPIC-HR study. https://t.co/1MMhqn4elw

— Paul Sax (@PaulSaxMD) April 25, 2022

 

---

Diretriz NICE | Medicamentos associados a dependência ou recidiva de sintomas: prescrição segura e retirada de tratamento para adultos.

27 Abr, 2022 | 15:51h

Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults – National Institute for Health and Care Excellence

---

Medicamentos anticolinérgicos e demência: deveríamos nos preocupar?

27 Abr, 2022 | 15:21h

Commonly-prescribed drugs and dementia: should we be worried? – Evidently Cochrane

Revisão original: Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome – Cochrane Library

Editorial: Anticholinergic drugs and dementia: time for transparency in the face of uncertainty – Cochrane Library

Conteúdos relacionados:

Quantifying Anticholinergic Burden and Sedative Load in Older Adults with Polypharmacy: A Systematic Review of Risk Scales and Models – Drugs & Aging

Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study – JAMA Internal Medicine

How well do you know your anticholinergic (antimuscarinic) drugs? – Therapeutics Initiative

Anticholinergic drugs and risk of dementia: case-control study – The BMJ

 

Comentário no Twitter

Commonly-prescribed drugs & dementia: should we be worried? https://t.co/pvWxT6q48Z A @CochraneUK blog: Jodi Watt (a researcher @UofGlasgow) explores the @CochraneDCIG evidence on whether #anticholinergics might increase people’s risk of future memory problems, or even #dementia

— The Cochrane Library (@CochraneLibrary) April 22, 2022

 

---

Perspectiva | Oncologia de precisão para pacientes com câncer.

27 Abr, 2022 | 15:19h

Delivering precision oncology to patients with cancer – Nature Medicine (gratuito por tempo limitado)

 

Comentário no Twitter

A Perspective in @NatureMedicine outlines the major challenges to the implementation of precision oncology and discusses critical steps toward resolving them. https://t.co/7l3WmFffn3 pic.twitter.com/oxFMZGZunf

— Nature Portfolio (@NaturePortfolio) April 24, 2022

 

---

OMS recomenda o nirmatrelvir-ritonavir para o tratamento da COVID-19 e pede para uma maior distribuição geográfica.

25 Abr, 2022 | 12:47h

WHO recommends highly successful COVID-19 therapy and calls for wide geographical distribution and transparency from originator – World Health Organization

Ver também:

A living WHO guideline on drugs for covid-19 – The BMJ

Therapeutics and COVID-19: living guideline – World Health Organization

Conteúdos relacionados:

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 – New England Journal of Medicine

Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions – Annals of Internal Medicine

The COVID-19 Treatment Guidelines Panel’s Statement on Potential Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications – NIH COVID-19 Treatment Guidelines Panel

 

Comentário no Twitter

🔥 Our latest @WHO living guidance on drugs for #COVID19, with new recommendations for nirmatrelvir-ritonavir & updated recommendation for remdesivir in non-severe illness.@bmj_latest: https://t.co/KuJjwzeTPV@WHO: https://t.co/n3iQx3pdmY@theMAGICapp: https://t.co/dA7YYzeAZ1 pic.twitter.com/LvAhJf70UY

— Arnav Agarwal (@ArnavAgarwalMD) April 21, 2022

 

---

Regulador de medicamentos do Reino Unido aconselha pacientes e médicos contra o uso de pregabalina durante a gestação em virtude de um possível risco aumentado de malformações congênitas.

25 Abr, 2022 | 12:40h

Pregabalin (Lyrica): findings of safety study on risks during pregnancy – Medicines and Healthcare products Regulatory Agency

Ver também: Pregabalin and risks in pregnancy – Medicines and Healthcare products Regulatory Agency

Fonte: Avoid prescribing pregabalin during pregnancy if possible, says UK drug regulator – The BMJ ($)

 

Comentário no Twitter

The Medicines and Healthcare Products Regulatory Agency (@MHRAgovuk) has strengthened its warning about avoiding pregabalin during pregnancy after new data showed an increased risk of major congenital malformations associated with the drug https://t.co/ghGvqCqA0C

— The BMJ (@bmj_latest) April 22, 2022

 

---

Estudo randomizado | AZD7442 (tixagevimabe–cilgavimabe) intramuscular para prevenir Covid-19.

25 Abr, 2022 | 12:29h

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19 – New England Journal of Medicine

 

Comentário no Twitter

AZD7442 (tixagevimab/cilgavimab) found to have about 76% efficacy in preventing symptomatic Covid-19 infection. https://t.co/8tmvz3xI4I pic.twitter.com/fOegZjBRA6

— NEJM (@NEJM) April 20, 2022

 

---

[Comunicado de imprensa – ainda não publicado] Novas diretrizes da OMS recomendam um tratamento mais simples e seguro para doença criptocócica em pessoas que vivem com HIV.

25 Abr, 2022 | 12:28h

New guidelines from WHO recommend a simpler, safer treatment for cryptococcal disease in people living with HIV – World Health Organization

Estudo relacionado: Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis – New England Journal of Medicine (link para o resumo – $ para o texto completo)

---